NuSirt Biopharma, OWL Metabolomics Partner

News   Sep 24, 2016

 
NuSirt Biopharma, OWL Metabolomics Partner
 
 
 

RELATED ARTICLES

Pre-Diabetes Discovery Marks Step Towards Precision Medicine

News

Identification of three molecules that can be used to accurately assess pre-diabetes – a key predictor of conditions such as diabetes and high blood pressure – has brought precision medicine for humans a step closer.

READ MORE

Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line Treatment

News

The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.

READ MORE

New Simple Test Could Help Cystic Fibrosis Patients Find Best Treatment

News

In a significant step toward personalized medicine for cystic fibrosis, a minimally-invasive technique shows promise as a fast, inexpensive indicator to help more patients access new treatments.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Diagnostics Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE